ERRATA

The May 20, 2009, abstract by Gershon et al, entitled “Effect of the combination of retinoic acid and rapamycin on cerebellar granule cell and medulloblastoma proliferation” (J Clin Oncol 27:106s, 2009 [suppl 15s; abstr 2077]), has been updated.

The second author’s name was originally given as A.K. Shirazi. It has been updated to A.K. Shiraz.

DOI: 10.1200/JCO.2014.59.2691; published October 20, 2014

The November 20, 2012, article by Younes et al, entitled “Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes” (J Clin Oncol 30:4161-4167, 2012), contained an error.

The clinical trial information was given as NCT00481091, whereas it should have been **NCT00741871**.

The online version has been corrected in departure from the print. The authors apologize for the error.

DOI: 10.1200/JCO.2014.59.2709; published October 20, 2014

The May 10, 2013, Original Report by Fizazi et al, entitled “Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients with Metastatic Castration-Resistant Prostate Cancer” (J Clin Oncol 31:1740-1747, 2013), contained an error.

The first author’s name was given incorrectly as Karim S. Fizazi. It should have been given as **Karim Fizazi**.

The authors apologize for the mistake.

DOI: 10.1200/JCO.2014.59.2717; published October 20, 2014

The February 1, 2014, article by Fields et al, entitled “De Novo Treatment of Diffuse Large B-Cell Lymphoma With Rituximab, Cyclophosphamide, Vincristine, Gemcitabine, and Prednisolone in Patients With Cardiac Comorbidity: A United Kingdom National Cancer Research Institute Trial” (J Clin Oncol 32:282-287, 2014), contained errors.

In the Abstract, the third sentence in the Patients and Methods section was given as “All patients had advanced disease; 27 (43.5%) had left ventricular ejection fraction of $\leq 50\%$, and 35 (56.5%) had borderline ejection fraction of $> 50\%$ but $\leq 55\%$ and comorbid cardiac risk factors such as ischemic heart disease, diabetes mellitus, or hypertension.”

It should have been given as, “All patients had advanced disease; 27 (43.5%) had left ventricular ejection fraction of $\leq 50\%$, and 35 (56.5%) had an ejection fraction **of $> 50\%$** and comorbid cardiac risk factors such as ischemic heart disease, diabetes mellitus, or hypertension.”

Additionally, the final independent clause of the first sentence of the third paragraph of the Patients and Methods section was given as, “In those with borderline ejection fractions and cardiac comorbid conditions, entry criteria were extended

to include patients with LVEF $> 50\%$ but $\leq 55\%$, provided they had documented cardiac comorbidities (hypertension, IHD, or DM) precluding anthracycline use according to the local investigator.”

It should have been given as, “In those with an ejection fraction and cardiac comorbid conditions, entry criteria were extended to include patients with **LVEF $> 50\%$** , provided they had documented cardiac comorbidities (hypertension, IHD, or DM) precluding anthracycline use according to the local investigator.”

Finally, the last sentence of the first paragraph in the Results section was given as, “Twenty-seven patients (43.5%) had cardiac ejection fraction $\leq 50\%$, and 35 (56.5%) had borderline ejection fraction > 50 but $\leq 55\%$ plus the presence of comorbid cardiac risk factors such as IHD, DM, or hypertension.”

It should have been given as, “Twenty-seven patients (43.5%) had cardiac ejection fraction $\leq 50\%$, and 35 (56.5%) had an ejection **fraction $> 50\%$** plus the presence of comorbid cardiac risk factors such as IHD, DM, or hypertension.”

The authors apologize for the mistakes.

DOI: 10.1200/JCO.2014.59.2733; published October 20, 2014